FindTrial
Sign In

NXP900

DRUG3 trials

Sponsors

Nuvectis Pharma, Inc.

Conditions

ALK PositiveALK Positive Non-small Cell Lung CancerALK+ Non-Small-Cell Lung CarcinomaAdvanced Solid TumorEGFR Mutated Non-small Cell Lung Cancer PatientsEGFR Mutation Positive Non-small Cell Lung CancerMesotheliomaNSCLC

Phase 1

A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers
RecruitingNCT05873686
Nuvectis Pharma, Inc.Advanced Solid Tumor, Mesothelioma, Non-small Cell Lung Adenocarcinoma +3
Start: 2023-10-26End: 2027-07-01Target: 140Updated: 2026-07-09
Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer
RecruitingNCT07315113
Nuvectis Pharma, Inc.EGFR Mutated Non-small Cell Lung Cancer Patients, EGFR Mutation Positive Non-small Cell Lung Cancer
Start: 2025-12-18End: 2027-06-01Target: 18Updated: 2026-07-09
Study of NXP900 With Lorlatinib in ALK+ Lung Cancer
RecruitingNCT07784959
Nuvectis Pharma, Inc.ALK+ Non-Small-Cell Lung Carcinoma, ALK Positive, ALK Positive Non-small Cell Lung Cancer +1
Start: 2026-08-17End: 2028-02-01Target: 54Updated: 2026-08-25

Related Papers

Abstract 5885: Targeting myeloid-derived suppressor cells (MDSCs) to restore antitumor immunity in non-small cell lung cancer (NSCLC) via SRC family kinase Inhibition with NXP900
Cancer Research2026-04-03
Abstract 6495: NXP900, a Phase 1b, first-in-class YES1/SRC inhibitor demonstrates potent synergy with KRAS inhibitors in KRASi sensitive and resistant NSCLC models
Cancer Research2026-04-03
Abstract CT153: First in human phase 1 trial of the SRC family kinase inhibitor NXP900 in patients with advanced solid tumors
Cancer Research2025-04-251 citations